At least three small-cap acquisition targets extended tender offer deadlines in the past fourteen days, a quiet but directional signal that merger financing remains strained below the $500 million enterprise value threshold. Assertio Holdings pushed its Garda Capital-led tender to March 14, while Soleno Therapeutics gave its bidder an additional ten business days. Both cited ongoing regulatory filings—but the pattern suggests something more structural.

The extensions arrive as leveraged loan spreads for sub-investment-grade borrowers widened 42 basis points since December, according to LCD data. Private equity sponsors backing these deals typically finance with 65-75% debt, and the marginal cost of delay is now lower than the cost of repricing covenants mid-close. Assertio's deal, a $236 million take-private, was announced in November at $8.50 per share. The stock trades at $8.44 today, a 71-basis-point discount that reflects neither arb compression nor deal certainty—just quiet skepticism.

What makes this cluster matter is the asset class. Small-cap M&A extensions are not headline events, but they foreshadow larger repricing cycles. When sub-$500 million deals stall, it signals that credit underwriters are tightening terms on the quietest part of the capital stack—the mezzanine and second-lien tranches that private equity uses to juice returns. If those terms worsen by 50-100 basis points, as they did in Q2 2023, the next wave of deals simply does not clear internal IRR hurdles. The extension is not the problem; it is the symptom of a financing market that no longer assumes certainty.

Soleno's extension is instructive. The company develops a metabolic disorder therapy with lumpy revenue and clinical-stage risk. Its acquirer needed extra time not for regulatory approval—those filings are routine—but to finalize debt commitments with lenders who now want tighter covenants and shorter tenor. That is a 2024 financing environment in a sentence: the deal gets done, but the terms drift.

Operators should track Hart-Scott-Rodman filing windows on these deals, which typically run 30 days but can extend if the FTC issues a second request. None of the current extensions cite antitrust delay, which means the friction is elsewhere—likely in syndication or covenant negotiation. Family offices and allocators watching private credit exposure should note that small-cap deal extensions often precede widening in the private credit benchmark, usually with a 45-60 day lag. If four more deals extend by mid-March, the signal becomes a pattern.

The specific follow-on event is covenant repricing in Q2 earnings calls. If these deals close with revised terms, sponsors will disclose leverage multiples and interest coverage ratios that deviate from initial announcements. That disclosure will confirm whether this is a February blip or a structural shift in how sub-$500 million M&A gets financed. The timeline is April 15 through May 10, when most of these targets report.

By March 21, at least two of these deals will either close with amended terms or terminate. The spread between those outcomes is the only number that matters.